MICROWAVE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA Sandia National Laboratories (SNL) offers to license its patented transurethral applicator for microwave treatment of benign prostatic hyperplasia (BPH). This applicator is distinguished from all other devices presently in use for this purpose by improved uniformity of fields induced in periurethral tissues. The benefit of this feature in clinical practice is greater treatment control thereby avoiding over-treatment leading to unnecessary complications or under-treatment leading to regrowth. The greater uniformity of fields induced by radiative transfer does not require movement or repositioning of the applicator and energy transfer to the periurtheral tissue is optimized for each patient. The technology involves a novel electromagnetic structure compatible with otherwise conventional catheter platforms. A urethral cooling loop and sensor package may be included. In addition to this direct license, SNL offers an opportunity for a CRADA to incorporate the new applicator into a complete microwave system for treatment of BPH. SNL's historic mission in radar brings a vast technology base to this development effort. Furthermore, SNL investment in Biophysics offers leverage of a CRADA partner's funds to complete tests in vitro of a new method of BPH treatment using the instant invention with RF systems that add a new, specific type of cellular injury. The new method and apparatus does not depend solely upon heat for treatment efficacy. Rather, modulation effects offer differential cellular injury to preserve normal tissue and optimize treatment effects upon hyperplastic cells. A CRADA partner would share the method and apparatus already developed by SNL to study modulation effects and benefit from the data produced in tests with our clinical partners for human prostate in vitro. Such tests could lead to new clinical tools for minimally invasive treatment of BPH. Sandia has an proprietary intellectual property position in the "Microwave Treatment of Benign..." technology. The technology isin the advanced stages of technology development, having started clinical testing. Approximately one-half million dollar investment has already gone into the technology. Sandia believes that the market potential for "Microwave Treatment..." is large. According to the Manufacturing USA Directory, sales in the surgical apparatus and instruments market is over $25 billion. Cases of prostate cancer are on the increase, and more effective treatment methods will be in high demand in the future. In order to fulfill fairness of opportunity requirements, Sandia will widely advertise both the technology and the fact that it may be licensed. Depending upon any prior commitments, the advertised license can take a variety of forms, up to and including the opportunity for an exclusive license. However keep in mind, that this is not an offer for the sale of a license, but rather a solicitation of interested parties for potential license opportunities. You and other potential licensees, must express interest in the technology either by writing or faxing us. The deadline for accepting respondents is December 16, 1996. In your inquiry, please include: the name of the technology, "Microwave Treatment of Benign..", and any information on your companies' experience/capabilities with similar technologies Write to: Joanne Trujillo Sandia National Laboratories Technology Partnerships Dept. PO Box 5800 -- MS 1380 Albuquerque, NM 87185-1380 .... or express interest by fax at (505) 843-4175 After you contact us, we will send you a short questionnaire to assess your company's ownership and size. Preference will be given to US based businesses. From there, Sandia will evaluate all replies. An offer for sale, consistent with the selected licensing strategy will then be developed. The chosen strategy will be mutually beneficial for both Sandia, and the chosen company or companies. We look forward to the opportunity to work with you and your company on the desired goal of commercialization of the Microwave Treatment of Benign Prostatic Hyperplasia technology. E-MAIL: Microwave Treatment of Benign Prostatic Hyperplasia,.

Loren Data Corp. http://www.ld.com (SYN# 0462 19961206\SP-0001.MSC)